Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pradnya Patil

Showing results (11-20 of 25) with videos related to

Pageof 3
Sort By:
Anti-Cancer Agents in Medicinal Chemistry|May 8, 2026
Nucleobase Ionic Liquids (NBILs) Induced Apoptosis via Caspase 3 Activation and in silico Regulation of the IRE1a Pathway in Pancreatic Cancer PANC-1 CellsPradnya Patil, Prakash Bansode, Gaurang Telang, et al.
Lung Cancer (Amsterdam, Netherlands)|August 27, 2019
Predicting pathologic response to neoadjuvant chemoradiation in resectable stage III non-small cell lung cancer patients using computed tomography radiomic featuresMohammadhadi Khorrami, Prantesh Jain, Kaustav Bera, et al.
Science Advances|November 25, 2022
A tumor vasculature-based imaging biomarker for predicting response and survival in patients with lung cancer treated with checkpoint inhibitorsMehdi Alilou, Mohammadhadi Khorrami, Prateek Prasanna, et al.
Lung Cancer (Amsterdam, Netherlands)|October 1, 2019
Corrigendum to "Predicting pathologic response to neoadjuvant chemoradiation in resectable stage III non-small cell lung cancer patients using computed tomography radiomic features" [Lung Cancer 135 (September) (2019) 1-9]Mohammadhadi Khorrami, Prantesh Jain, Kaustav Bera, et al.
Cancer Immunology Research|November 14, 2019
Changes in CT Radiomic Features Associated with Lymphocyte Distribution Predict Overall Survival and Response to Immunotherapy in Non-Small Cell Lung CancerMohammadhadi Khorrami, Prateek Prasanna, Amit Gupta, et al.
Journal for Immunotherapy of Cancer|March 8, 2022
Novel imaging biomarkers predict outcomes in stage III unresectable non-small cell lung cancer treated with chemoradiation and durvalumabKhalid Jazieh, Mohammadhadi Khorrami, Anas Saad, et al.
The Lancet. Digital Health|March 4, 2020
CT derived radiomic score for predicting the added benefit of adjuvant chemotherapy following surgery in Stage I, II resectable Non-Small Cell Lung Cancer: a retrospective multi-cohort study for outcome predictionPranjal Vaidya, Kaustav Bera, Amit Gupta, et al.
Clinical Lung Cancer|October 4, 2025
Pembrolizumab in Combination With Platinum-Based Chemotherapy in Patients With Recurrent EGFR and ALK Gene Altered Non-Small-Cell Lung Cancer (NSCLC)Shirish M Gadgeel, Misako Nagasaka, Karen Dziubek, et al.
Lung Cancer (Amsterdam, Netherlands)|March 3, 2020
Stable and discriminating radiomic predictor of recurrence in early stage non-small cell lung cancer: Multi-site studyMohammadhadi Khorrami, Kaustav Bera, Patrick Leo, et al.
Scientific Reports|January 18, 2022
Author Correction: Impact of KRAS mutation status on the efficacy of immunotherapy in lung cancer brain metastasesAdam Lauko, Rupesh Kotecha, Addison Barnett, et al.
Pageof 3

Showing results (11-20 of 25) with videos related to

Sort By:
Pageof 3
Anti-Cancer Agents in Medicinal Chemistry|May 8, 2026
Nucleobase Ionic Liquids (NBILs) Induced Apoptosis via Caspase 3 Activation and in silico Regulation of the IRE1a Pathway in Pancreatic Cancer PANC-1 CellsPradnya Patil, Prakash Bansode, Gaurang Telang, et al.
Lung Cancer (Amsterdam, Netherlands)|August 27, 2019
Predicting pathologic response to neoadjuvant chemoradiation in resectable stage III non-small cell lung cancer patients using computed tomography radiomic featuresMohammadhadi Khorrami, Prantesh Jain, Kaustav Bera, et al.
Science Advances|November 25, 2022
A tumor vasculature-based imaging biomarker for predicting response and survival in patients with lung cancer treated with checkpoint inhibitorsMehdi Alilou, Mohammadhadi Khorrami, Prateek Prasanna, et al.
Lung Cancer (Amsterdam, Netherlands)|October 1, 2019
Corrigendum to "Predicting pathologic response to neoadjuvant chemoradiation in resectable stage III non-small cell lung cancer patients using computed tomography radiomic features" [Lung Cancer 135 (September) (2019) 1-9]Mohammadhadi Khorrami, Prantesh Jain, Kaustav Bera, et al.
Cancer Immunology Research|November 14, 2019
Changes in CT Radiomic Features Associated with Lymphocyte Distribution Predict Overall Survival and Response to Immunotherapy in Non-Small Cell Lung CancerMohammadhadi Khorrami, Prateek Prasanna, Amit Gupta, et al.
Journal for Immunotherapy of Cancer|March 8, 2022
Novel imaging biomarkers predict outcomes in stage III unresectable non-small cell lung cancer treated with chemoradiation and durvalumabKhalid Jazieh, Mohammadhadi Khorrami, Anas Saad, et al.
The Lancet. Digital Health|March 4, 2020
CT derived radiomic score for predicting the added benefit of adjuvant chemotherapy following surgery in Stage I, II resectable Non-Small Cell Lung Cancer: a retrospective multi-cohort study for outcome predictionPranjal Vaidya, Kaustav Bera, Amit Gupta, et al.
Clinical Lung Cancer|October 4, 2025
Pembrolizumab in Combination With Platinum-Based Chemotherapy in Patients With Recurrent EGFR and ALK Gene Altered Non-Small-Cell Lung Cancer (NSCLC)Shirish M Gadgeel, Misako Nagasaka, Karen Dziubek, et al.
Lung Cancer (Amsterdam, Netherlands)|March 3, 2020
Stable and discriminating radiomic predictor of recurrence in early stage non-small cell lung cancer: Multi-site studyMohammadhadi Khorrami, Kaustav Bera, Patrick Leo, et al.
Scientific Reports|January 18, 2022
Author Correction: Impact of KRAS mutation status on the efficacy of immunotherapy in lung cancer brain metastasesAdam Lauko, Rupesh Kotecha, Addison Barnett, et al.
Pageof 3